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Available online 14 May 2016Introduction: From a series of radiolabelled cholecystokinin (CCK) and gastrin analogues, 111In-CP04 (111In-
DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) was selected for further translation as a diagnostic radio-
pharmaceutical towards a first-in-man study in patients with medullary thyroid carcinoma (MTC). A freeze-
dried kit formulation for multicentre application has been developed. We herein report on biosafety, in vivo sta-
bility, biodistribution and dosimetry aspects of 111In-CP04 in animalmodels, essential for the regulatory approval
of the clinical trial.
Materials and methods: Acute and extended single dose toxicity of CP04 was tested in rodents, while the in vivo
stability of 111In-CP04 was assessed by HPLC analysis of mouse blood samples. The biodistribution of 111In-CP04
prepared from a freeze-dried kit was studied in SCIDmice bearing double A431-CCK2R(±) xenografts at 1, 4 and
24 h pi. Further 4-h animal groups were either additionally treated with the plasma expander gelofusine or
injected with 111In-CP04 prepared by wet-labelling. Pharmacokinetics in healthy mice included the 30 min, 1,
4, 24, 48 and 72 h time points pi. Dosimetric calculations were based on extrapolation of mice data to humans
adopting two scaling models.
Results: CP04 was well-tolerated by both mice and rats, with an LD50 N 178.5 μg/kg body weight for mice and a
NOAEL (no-observed-adverse-effect-level) of 89 μg/kg bodyweight for rats. After labelling, 111In-CP04 remained
N70% intact in peripheral mouse blood at 5 min pi. The uptake of 111In-CP04 prepared from the freeze-dried kit
and by wet-labelling were comparable in the A431-CCK2R(+)-xenografts (9.24 ± 1.35%ID/g and 8.49 ±
0.39%ID/g, respectively; P N 0.05). Gelofusine-treated mice exhibited significantly reduced kidneys values
(1.69±0.15%ID/g vs. 5.55±0.94%ID/g in controls, P b 0.001). Dosimetry data revealed very comparable effective
tumour doses for the two scaling models applied, of 0.045 and 0.044 mSv/MBq.
Conclusion: The present study has provided convincing toxicology, biodistribution and dosimetry data for prompt
implementation of the freeze-dried kit formulation without or with gelofusine administration in a multicentre
clinical trial in MTC patients.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Gastrin-radioligand
Radionuclide therapy
Clinical translationMedicine, Innsbruck Medical
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. This is an open access article under1. Introduction
Medullary thyroid cancer (MTC) is a neuroendocrine tumour of the
parafollicular or C cells of the thyroid, not accumulating iodine. It ac-
counts for 3% to 5% of thyroid carcinomas (Pacini et al., 2010; Wells et
al., 2015). In many cases disease has already metastasized at the timethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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radiotherapy or systemic therapy are uncommon (Pacini et al., 2010)
and new targeted chemotherapy approaches (like tyrosine kinase in-
hibitors, TKI) show significant toxicity and do not change overall surviv-
al is (Nikiforova and Nikiforov, 2008; Zhang et al., 2009). MTC therefore
still remains a highly challenging cancer for both the patient and the
physician.
Molecular nuclear medicine can play an important role in diagnosis
(SPECT/CT, PET/CT) and therapy of advanced MTC (Reubi and Maecke,
2008). Molecular imaging and peptide receptor radionuclide therapy
(PRRT) approaches can exploit the overexpression of cholecystokinin
subtype 2 receptors (CCK2R) at an incidence of over 90% in MTC
(Reubi et al., 1997; Reubi andWaser, 1996). This finding has motivated
a number of research groups to develop site-specific radiolabeled ana-
logues of cholecystokinin-8 (CCK-8; Asp-Tyr-Met-Gly-Trp-Met-Asp-
Phe-NH2) or minigastrin (MG, Leu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-
Phe-NH2). (Behr and Behe, 2002; Froberg et al., 2009; Nock et al.,
2005; Sosabowski et al., 2007; von Guggenberg et al., 2004; von
Guggenberg et al., 2007).
The very high kidney retention of these tracers, which limits their ap-
plication for radionuclide therapy (Behe and Behr, 2002), has stimulated
further research which revealed the importance of the multi-negative
charges of the penta-Glu chain but also of the secondary peptide structure
on the in vivo profile of resultingminigastrin radioligands (Breeman et al.,
2008; Good et al., 2008; Kolenc-Peitl et al., 2011; Kolenc Peitl et al., 2015;
Mather et al., 2007; von Guggenberg et al., 2009, 2012).
From a series of such analogues the linear peptide radioligand 111In-
DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (111In-CP04, also
named PPF11; Fig. 1) was selected as the best candidate for a subse-
quent phase I clinical study in the diagnosis and therapy of human
MTC, owing to its high tumour uptake and retention aswell as the favor-
able tumour-to-kidney ratios attained (Aloj et al., 2011; Laverman et al.,
2011; Ocak et al., 2011).
For conducting a multicenter clinical trial in Europe, an Investiga-
tional Medicinal Product Dossier (IMPD) has to be submitted and ap-
proved by the Authorities. Such IMPD is based on the common
technical dossier (CTD) which for radiopharmaceuticals should addi-
tionally include information related to radioactivity and radiolabelling
procedures (Todde et al., 2014). Data on the chemical and pharmaceu-
tical development and characterization of a freeze-dried kit formulation
for radiolabelling of the radiopharmaceutical precursor CP04 with 111In
(chapter 2.1 of the CTD) has been recently presented (Pawlak et al.,
2016). We herein further describe the additional data generated for
translating this promising radiopharmaceutical into a first in human
clinical trial. This includes the non-clinical pharmacology, pharmacoki-
netics and toxicity data. Initial preclinical data already have been report-
ed (Aloj et al., 2011; Laverman et al., 2011;Ocak et al., 2011; Kolenc Peitl
et al., 2015). In the present work we additionally report on the specific
requirements for a radioactive medicinal product, including specific
toxicity studies (Koziorowski et al., 2016), animal tumour models and
estimation of the expected human radiation dose extrapolated from an-
imal data, essential for the regulatory approval of the clinical trial.Fig. 1. Chemical structure of 111In-CP04 with the DGlu1–6-chain highlighted in blue. (For interp
version of this article.)2. Materials and methods
2.1. Chemicals and peptides
If not otherwise stated, chemicals, materials and solvents were of
pharmaceutical grade for kit preparation and reagent grade for other
experiments and were used without further purification. L-methionine
was provided by SAFC chemicals (Cleveland OH), ascorbic acid and
gentisic acid (Ultrapure quality) were provided by Sigma Aldrich (St.
Louis, MO). The CP04-precursor in GMP grade was provided by PiChem
(Graz, Austria) and CP04 freeze-dried kits for the preparation of 111In-
CP04 were prepared as previously described (Pawlak et al., 2016).
2.2. Animals
For acute intravenous toxicity studies Crl:NMRI (SPF) female mice
provided by Charles River Laboratories (Germany) of 7–9 weeks of
age and a body weight of 26–33 g were used. For extended acute single
dose toxicity study in rats, 45 female and 45 male Wistar Hannover
RccHan™ rats were used purchased from Harlan Laboratories, B.V.
(The Netherlands). Animals were 7–7 weeks of age and the body
weights were 195–235 g for males and 164–199 g for females. For in
vivo stability tests and biodistribution/dosimetry studies healthy male
Swiss albino mice from NCSR “Demokritos” Animal House were used,
of 8–10 weeks of age and a body weight of 20–25 g. For the CCK2R-ex-
pressing tumour model, male SCID mice from NCSR “Demokritos” Ani-
mal House were used, of 6 weeks of age on arrival day and a body
weight of 20 ± 2 g.
2.3. Toxicity studies
2.3.1. Acute toxicity of CP04 in mice
The CP04 precursor was dissolved in phosphate buffered saline (PBS
pH 7.4) and was administered at a dose of 178.5 μg/kg body weight and
a dose volume of 5 mL/kg body weight into the caudal vein of two
groups of three mice (Acute Intravenous Toxicity Study in Mice, Harlan
Laboratories Study #D04314). The test procedureswere based on OECD
Guideline 423 “Acute Oral Toxicity – Acute Toxic Class Method”,
adopted on 17th December 2001. In brief, the animals were examined
daily during the acclimatisation period. Mortality, viability and clinical
signswere recorded. All animalswere examined for clinical signswithin
thefirst 30min and approximately 1, 2, 3 and 5 h after treatment on test
day 1 and once daily during test days 2–15. Mortality/viability was re-
corded within the first 30 min and approximately 1, 2, 3 and 5 h after
administration on test day 1 (with the clinical signs) and twice daily
during days 2–15. Body weights were recorded on test day 1 (prior to
administration) and on test days 8 and 15. All animals were necropsied
and examined macroscopically.
2.3.2. Extended acute single dose toxicity study in rats
The studywas designed according to themicrodosing concept as de-
scribed in ICH guideline M3 (R2) (“Note for guidance on non-clinicalretation of the references to colour in this figure legend, the reader is referred to the web
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thorization for pharmaceuticals” (CPMP/ICH/286/95)). In brief, 90 rats
were distributed into three dose groups, each containingfifteen animals
per sex (Table 1). The animals from Group 1 received only PBS, serving
as controls, while groups II and III received the CP04 solution by single
intravenous (bolus) injection at a low (89 μg/kg body weight: Group
2) and a high dose (890 μg/kg body weight: Group 3). A 24-h observa-
tion period followed (Allocation A), except for five animals per sex
from each group for which treatment was followed by an additional
14-day treatment-free recovery period (Allocation B).
At day 2 blood samples were withdrawn from Allocation-A animals
for haematology, clinical biochemistry and samples for urinary analyses
were collected. These animals were necropsied on the same day and
histological examinationswere performed on an extended set of organs
(adrenal glands, kidneys, liver, pancreas, sternum (including bonemar-
row), small intestine, stomach, thyroid/parathyroid glands and gross le-
sions). The animals from Allocation-B remained untreated for the
following 14 days, but on day 15 underwent the same procedure de-
scribed above (Extended Acute Intravenous (Bolus) Toxicity Study in
Rats, Harlan Study #S47364).
2.4. Radiolabeling and quality control
For labelling, a sterile, non-pyrogenic solution of non-carrier-added
111InCl3 in 0.05 M HCl was supplied fromMallinckrodt Medical (Petten,
NL). The solution contained 185 MBq (5 mCi) of 111InCl3 per 0.5 mL at
time of calibration (specific activity of N1.85 GBq/μg indium at time of
calibration). CP04 (10 μg POLATOM kit, 4.88 nmol) was dissolved in
400 μL water for injection (Pharm.Eur., Fresenius Kabi, Halden, Nor-
way), 111InCl3 was added (~120 μL, 94.35MBq) and themixturewas in-
cubated for 12 min at 85 °C. The “wet-labelling” of CP04 with 111In was
completed in an Eppendorf vial. Freshly prepared sodium ascorbate
buffer (10 mM) was added in the vial, followed by 111InCl3 solution
(37–74 MBq), Met (1000 nmol) and CP04 (10 nmol). The mixture was
left to react at 80 °C for 20 min. Before quality control tests, EDTA in
0.1 M acetate buffer (pH 4.6) was added to a final concentration of
1 mM to the labelling reaction mixture as a “free” 111In3+ scavenger.
Quality control was conducted by HPLC analysis on (system 1) a RP-
18 XTerra column (5 μm, 3.9 mm × 20 mm) eluted at a flow rate of
1 mL/min with the linear gradient: 100% A/0% B to 40% A/60% B within
60 min (A = 0.1% aqueous TFA and B = MeCN).
2.5. In vivo stability of 111In-CP04 in mice
A bolus of 111In-CP04 (100 μL, 11 MBq, ≈3 nmol peptide) was
injected in the tail vein of healthymice. Bloodwithdrawn 5min post in-
jection (pi) was directly placed in pre-chilled polypropylene tubes con-
taining EDTA and Met on ice. Samples were centrifuged (10 min,
2000 ×g/4 °C, in a Hettich, Universal 320R, centrifuge, Tüttlingen, Ger-
many), plasma was collected, mixed with chilled MeCN in a 1/1 v/v
ratio and centrifuged again (10 min, 15,000 ×g/4 °C). Supernatants
were concentrated to a small volume under a gentle N2-flux at 40 °C, di-
luted with physiological saline (≈400 μL) and filtered through a Millex
GV filter (0.22 μm). Aliquots thereof were analysed by HPLC under theTable 1
Number of wistar rats per group according to dose, sex and monitoring.
Groups 1* (control) 2 3
Treatment Vehicle CP04 CP04
Dose levels 0 μg/kg 89 μg/kg 890 μg/kg
Male A 10 10 10
Male B 5 5 5
Female A 10 10 10
Female B 5 5 5
A: animals formain study (Allocation A); B: animals for recovery (Allocation B); 1*: group
1 received vehicle only.following conditions (system 2): A RP-18 Symmetry Shield column
(5 μm, 3.9 mm × 20 mm) was eluted at a flow rate of 1 mL/min with
the linear gradient: 100% A/0% B to 40% A/60% B within 60 min (A =
0.1% aqueous TFA and B=MeCN); the tR of intact 111In-CP04was deter-
mined by co-injection of a parent radioligand sample.
2.6. Pharmacokinetics of 111In-CP04 in healthy mice
A bolus of 111In-CP04 (100 μL, 111 kBq, 10 pmol peptide) was
injected via the tail vein in healthy mice and animals were euthanized
in groups of four at 30 min, 1 h, 4 h, 24 h, 48 h and 72 h pi. Samples of
blood and tissues of interest were excised, weighted and counted for ra-
dioactivity in the gamma counter (automated well-type multi-sample
gamma counter; NaI(Tl) 3″ crystal, Canberra Packard Auto-Gamma
5000 series instrument). Data was calculated as percent injected dose
per gram tissue (%ID/g)with the aid of suitable standards of the injected
dose.
2.7. Biodistribution of 111In-CP04 in mice bearing double A431-CCK2R(±)
xenografts
The human epidermoid A431 cell line transfected to stably express
the CCK2R (A431-CCK2R(+)) or devoid of CCK2R expression (A431-
CCK2R(−)) used for tumour induction in this work was a gift from
Prof. O. Boerman (Department of NuclearMedicine, RadboudUniversity
Nijmegen Medical Centre, Nijmegen, The Netherlands) and Prof. L. Aloj
(Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle
Ricerche, Naples, Italy) and cells were cultured as previously reported
(Aloj et al., 2004). Suspensions of freshly harvested A431-CCK2R(±)
cells (~150 μL, 1.6 × 107/1.4 × 107) in normal salinewere subcutaneous-
ly injected in the flanks of mice. A week later well palpable tumours
(260 ± 80 mg) developed at the inoculation sites and biodistribution
was conducted.
At the day of the experiment, a bolus of 111In-CP04 (100 μL, 111 kBq,
10 pmol peptide)was injected in the tail vein ofmice. Animals were eu-
thanized in groups of four at 1 h, 4 h and 24 h pi; in a separate 4-h group
animals received gelofusine (100 μL) together with the radioligand. A
further 4-h group of mice was injected with 111In-CP04 prepared by
“wet labelling” (100 μL, 111 kBq, 10 pmol peptide). Micewere dissected
and samples of blood and tissues of interest aswell as tumourswere ex-
cised, weighted and counted for radioactivity in the gamma counter.
Data was calculated as percent injected dose per gram tissue (%ID/g)
with the aid of suitable standards of the injected dose and represent
mean ± SD. In all above experiments, analysis of the solution used in
the biodistribution experiment was conducted prior to and after com-
pletion of all animal injections.
Statistical analysis using the unpaired two-tailed Student's t-test
was performed to compare values between A431-CCK2R(+) and
A431-CCK2R(−) tumours, as well as kidney, stomach and A431-
CCK2R(+) tumour values between 4 h control and gelofusine-treated
animal groups; values P b 0.05 were considered statistically significant
(Table 2). The pharmacokinetic profile was determined by fitting an ex-
ponential curve through the organ time-activity data according to the
least-squares method. The number of exponentials in the fitted curve
was analysed according to the Aikake Information Criterion (AICc). All
fitting was performed with Graphpad Prism version 5.
All animal experiments were approved by national authorities and
were carried out in compliance with national and European guidelines.
2.8. Dosimetric calculations
Dosimetric calculations were based on biodistribution of 111In-CP04
in healthy mice from 30 min to 72 h pi (Table 2). Clearance kinetics in
each organwas determined by exponential curve fitting. The time-inte-
grated activity concentration (TIAC) was obtained by integration of this
exponential curve foldedwith the decay curve of 111In and 177Lu. Mouse
Table 2
Biodistribution of 111In-CP04 in healthy Swiss albino mice.
Organs
%ID/g tissue ± SD (n = 4)
111In-CP04
30 min 1 h 4 h 24 h 48 h 72 h
Blood 1.74 ± 0.22 0.51 ± 0.14 0.02 ± 0.01 0.00 ± 0.00 0.01 ± 0.01 0.01 ± 0.01
Liver 0.77 ± 0.11 0.32 ± 0.15 0.12 ± 0.02 0.06 ± 0.01 0.06 ± 0.00 0.05 ± 0.01
Heart 0.70 ± 0.10 0.21 ± 0.04 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.03 ± 0.02
Kidneys 9.80 ± 2.07 8.84 ± 2.05 7.90 ± 1.98 3.61 ± 0.31 2.81 ± 0.63 2.62 ± 0.24
Stomach 4.88 ± 0.85 2.99 ± 0.55 2.61 ± 0.82 1.48 ± 0.55 1.26 ± 0.26 0.92 ± 0.04
Intestines 0.82 ± 0.14 0.39 ± 0.12 1.05 ± 0.35 0.18 ± 0.14 0.08 ± 0.02 0.09 ± 0.04
Spleen 0.36 ± 0.04 0.14 ± 0.04 0.05 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.04 ± 0.01
Muscle 0.59 ± 0.10 0.18 ± 0.04 0.04 ± 0.02 0.02 ± 0.01 0.03 ± 0.02 0.03 ± 0.02
Lung 1.05 ± 0.10 0.40 ± 0.10 0.06 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01
Femur 4.62 ± 1.24 2.62 ± 0.42 0.96 ± 0.18 0.53 ± 0.04 0.55 ± 0.11 0.49 ± 0.06
Pancreas 0.67 ± 0.08 0.26 ± 0.08 0.10 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 0.06 ± 0.03
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the 25 g RADAR mouse absorbed dose rates per unit activity S for
each source and target organ combination (Keenan et al., 2010;
Konijnenberg et al., 2014).
Extrapolation of biodistribution uptake data in mice to humans was
based on two options for interspecies scaling (Stabin, 2008).
%IA
organ
 
human
¼ %IA
g
 
mouse
Mmouse kgð Þ
 
 m gð Þ
M kgð Þ
 
human
1:
with m the organ mass and M the total body weight of mouse or
human andwith%IAg and
%IA
organ the percentage of the injected activity con-
centration and per organ, respectively. Themouse organ TIACs are mul-
tiplied with the ratio of mouse and human body weights MmouseMhuman to obtain
the extrapolated human TIAC, and this multiplied with the organ mass
(from the MIRD standard man phantom) yields the residence time in
each source organ.
%IA
organ
 
human
¼ %IA
organ
 
mouse
¼ %IA
g
 
mouse
mmouse 2:
in thismethod the uptake per organ is extrapolated one-to-one from
mouse to man. The extrapolated human residence time is obtained by
multiplying the mouse TIAC or each source organ with its mouse
organ mass.
The extrapolated human source organ residence times were used as
input in the Olinda/EXM dosimetry software to calculate the absorbed
doses per administered activity in humans (Stabin et al., 2005).Fig. 2. Typical HPLC (system 2) radiochromatogram of blood sample collected 5 min after
intravenous injection of 111In-CP04 in Swiss albino mice with 70% intact radiotracer still
detected; the tR of intact 111In-CP04 is indicated by the arrow.3. Results
3.1. Toxicology
3.1.1. Acute toxicity of CP04 in mice
All animals survived until the end of the study with no systemic
signs of toxicity evident throughout the entire observation period. The
animal body weight was within the range commonly recorded for this
strain and age. No macroscopic findings were recorded at necropsy.
Themedian lethal dose (LD50) of CP04 after single intravenous adminis-
tration to femalemice observed over a period of 14 dayswas found to be
≥178.5 μg/kg body weight.3.1.2. Extended acute single dose toxicity of CP04 in rats
All animals survived the 24-h study period with no clinical signs
being recorded. Under the experimental conditions, single bolus injec-
tion of CP04 in rats at a dose of 890 μg/kg bodyweight caused a moder-
ate decrease in mean food consumption and body weight -gain and a
marked decrease in the reticulocyte count in the male rats 14 days
after administration. Based on pathological examination, the no-ob-
served-adverse-effect-level (NOAEL) was initially established at
890 μg/kg bodyweight. However, the reversibility of the effect recorded
in the reticulocyte count remained unknown and it was not possible to
assess whether it represents a true adverse effect. Accordingly, the
lower dose of 89 μg/kg body weight was eventually set as NOAEL, sup-
ported also by the absence of toxicological adverse alterations in mor-
phology, functional capacity, growth, development or life-span of
treated animals.
3.2. Metabolic stability of 111In-CP04 in mice
According to the HPLC analysis of mouse blood samples collected
5 min pi N 70% of 111In-CP04 remained intact in peripheral mouse
blood. A radiochromatogram of a representative mouse blood sample
is included in Fig. 2.
3.3. Biodistribution of 111In-CP04 in healthy mice
Biodistribution data of 111In-CP04 in healthymice at 30min, 1, 4, 24,
48 and 72 h pi is summarized in Table 2 as %ID/g (mean ± SD, n = 4),
whereas time-dependent clearance curves selectively for kidneys,
stomach, liver, intestines and blood are included in Fig. 3. The radiotrac-
er cleared very rapidly from the blood and the body of mice predomi-
nantly via the kidneys and the urinary tract. Radioactivity was
retained mainly in the stomach (a CCK2R-positive organ) and in the
kidneys.
Fig. 3. Time-dependent radioactivity clearance after injection of 111In-CP04 in Swiss albino
mice shown for selected tissues; kidneys, stomach, intestines, liver, blood;
values represent mean %ID/g ± SD, n = 4. Single-exponential fits through the data are
shown by the curves with corresponding color. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 4. Biodistribution of 111In-CP04 ( ) prepared by wet-labelling, ( ) after kit-
reconstitution and ( ) during gelofusine coinjection in A431-CCK2R(+) tumour bearing
SCID mice at 4 h pi. Results expressed as mean %ID/g ± SD are selectively shown for
comparison for Tu(+): tumour, Ki: kidneys and Tu(+)/Ki: tumour-to-kidney ratios.
Statistical analyses were performed using the unpaired two-tailed Student's t-test.
240 T. Maina et al. / European Journal of Pharmaceutical Sciences 91 (2016) 236–2423.4. Biodistribution in A431-CCK2R(±) tumour-bearing mice
Biodistribution data of 111In-CP04 in mice bearing double A431-
CCK2R(±) xenografts at 1, 4, and 24 h pi is presented in Table 3 as
%ID/g (mean ± SD, n = 4). Additional animal groups at 4 h pi are also
included in the Table 3, corresponding to mice coinjected with
gelofusine or receiving 111In-CP04, prepared by wet-labelling. Selective
data for A431-CCK2R(+) tumours, kidneys and kidney-to-blood ratios
for 4-h animal groups is included in Fig. 4 for comparison. In agreement
to findings of the healthymice study, the radiotracer cleared very rapid-
ly from the blood and the background via the kidneys and the urinary
system, showing some retention in the CCK2R-possitive stomach and
in the kidneys. It is interesting to note that gelofusine coinjection in-
duced a significant (P b 0.001) reduction of renal uptake from 5.55 ±Table 3
Biodistribution of 111In-CP04 in SCID mice bearing double A431-CCK2R(±) xenografts.
Organs
%ID/g tissue, mean ± sd (n = 4)
[111In]CP04
1 h 4 h 4 h + gelo 4 h ref. 24 h
Blood 0.55 ± 0.17 0.02 ± 0.01 0.02 ± 0.01 0.04 ± 0.02 0.00 ± 0.00
Liver 0.38 ± 0.12 0.11 ± 0.01 0.17 ± 0.14 0.12 ± 0.02 0.01 ± 0.01
Heart 0.24 ± 0.08 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.00
Kidneys 5.53 ± 0.78 5.55 ± 0.94 1.69 ±
0.15***
6.52 ±
0.63ns
3.29 ± 0.56
Stomach 2.60 ± 0.48 2.09 ± 0.32 2.15 ±
0.24ns
1.63 ± 0.20 1.58 ± 0.15
Intestines 0.36 ± 0.13 0.22 ± 0.08 0.39 ± 0.13 0.29 ± 0.18 0.10 ± 0.04
Spleen 0.18 ± 0.04 0.04 ± 0.02 0.07 ± 0.01 0.06 ± 0.02 0.05 ± 0.01
Muscle 0.14 ± 0.05 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 0.01 ± 0.01
Lung 0.47 ± 0.13 0.04 ± 0.01 0.05 ± 0.03 0.04 ± 0.01 0.03 ± 0.01
Femur 0.96 ± 0.46 0.30 ± 0.22 0.27 ± 0.02 0.39 ± 0.08 0.24 ± 0.09
Pancreas 0.23 ± 0.08 0.06 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.05 ± 0.01
Tumour(+) 12.60 ± 1.73 9.24 ± 1.35 7.99 ±
2.45ns
8.49 ±
0.39ns
4.98 ± 0.56
Tumour(−) 1.07 ±
0.29+++
0.19 ±
0.05+++
0.22 ±
0.03+++
0.14 ±
0.02+++
0.10 ±
0.02+++
Statistical analysis was performed using the Student's t-test with P values indicating very
significant (***/+++P b 0.001) and not significant (ns, P N 0.05) difference (+) between
Tumour(+) (A431-CCK2R(+)) and Tumour(−) (A431-CCK2R(−)) and (*) between the
4 h and 4 h+ gelofusine-treatedmice. The values in column 4 h-ref. correspond to a sep-
arate group of mice injected with 111In-CP04 obtained by “wet-labelling”; no significant
differences were observed between this group and the 4-h group injected with 111In-
CP04 prepared by kit reconstitution.0.94%ID/g to 1.69 ± 0.15%ID/g at 4 h pi, with the radioactivity excreted
rapidly into urine. A CCK2R-independent process seems to be involved
in the prolonged retention of the radiotracer in mouse kidney, since
the CCK2R-positive stomach and tumour were not affected by
gelofusine injection.
Another significant finding is the indistinguishable biodistribution
profile between the 111In-CP04 prepared from the freeze-dried kit and
from wet-labelling. No significant difference in the radioactivity levels
in the A431-CCK2R(+) tumours was observed between kit and wet-la-
belling animal groups (9.24 ± 1.35%ID/g and 8.49 ± 0.39%ID/g, respec-
tively; P N 0.05), or between untreated and gelofusine-treated mice
(9.24 ± 1.35%ID/g and 7.99 ± 2.45%ID/g, respectively; P N 0.05). The
high uptake of the radiotracer in the human xenografts expressing the
CCK2R, but not in the tumours devoid of CCK2R-expression suggests
in vivo CCK2R-specificity.
3.5. Dosimetric calculations
Total body clearance was calculated to be 90% with T1/2 = 17 min
and 10% with T1/2 = 38 h, whereas a gastrointestinal tract clearance of
2.5% was observed. Mouse dosimetry was calculated for both 111In and
177Lu and is presented in Table 4. Based on mouse data and adopting
two interspecies scaling models for extrapolating animal to human
data the expected absorbed doses per injected activity in humans
were calculated, leading to very comparable effective doses for both op-
tions of 0.045 and 0.044 mSv/MBq (Table 5). Assuming a radioactivity
dose of 220 MBq 111In is injected in a patient, a whole body radiation
dose of 9.9mSv should be expected. This estimation needs to be eventu-
ally verified during the clinical study.Table 4
Dosimetry of 111In-CP04 and 177Lu-CP04 in mice.
Organs
Absorbed dose per injected activity
(mGy/MBq)
111In-CP04 177Lu-CP04
Kidneys 56 400
Stomach wall 15 86
Bone 9 51
Large intestine 7 36
Small intestine 7 36
Total body 4 19
Pancreas 5 16
Lungs 3 12
Spleen 3 9
Liver 3 7
Table 5
Expected absorbed doses of 111In-CP04 in humans based on two scaling models for trans-
lating mouse to human data.
Organs
Absorbed dose per injected activity
(mGy/MBq)
Option 1 Option 2
LLI wall 0.078 0.075
Small intestine 0.026 0.024
Stomach wall 0.012 0.011
ULI wall 0.037 0.035
Heart wall 0.005 0.003
Kidneys 0.039 0.124
Liver 0.005 0.009
Lungs 0.004 0.003
Muscle 0.010 0.009
Pancreas 0.008 0.017
Red marrow 0.010 0.012
Osteogenic cells 0.015 0.034
Spleen 0.007 0.011
Urinary bladder wall 0.459 0.456
Total body 0.011 0.010
Effective dose (mSv/MBq) 0.045 0.044
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The therapeutic options for metastatic MTC are quite limited.
Whereas classical cytotoxic chemotherapies are often linked to life-
threatening toxicity, many novel targeted therapies (such as TKIs), al-
though less toxic, still show considerable side effects. As a result, these
systemic treatments are justified only for patients at significant risk of
morbidity or mortality due to progressive spread disease. The rational
design of new effective and less toxic site-directed drugs exploits the
overexpression of molecular targets in MTC to specifically deliver cyto-
toxic loads to tumour cells. For example, minigastrin-based radionu-
clide carriers may deliver cytotoxic radiation to MTC lesions via
CCK2R-targets on tumour cells while at the same time sparing sur-
rounding healthy tissue. To improve the efficacy and limit the side-ef-
fects of this approach, radiolabeled minigastrin analogues should
show high CCK2R-affinity, good in vivo stability for sufficient delivery
to tumour-associated targets, rapid blood and physiological organ clear-
ance preferably through the kidneys into urine. All above parameters
are considered essential to optimize tumour to background ratios and
thereby the therapeutic index of radiolabeled minigastrin analogues.
According to reported results, CP04 and 111/natIn-CP04 showed high
CCK2R-affinity with the respective IC50s found in the lower nM range
(Aloj et al., 2011; Kolenc Peitl et al., 2015). The 111In-CP04 radiotracer
previously shown to be very stable in serum (Kolenc Peitl et al., 2015)
and in animal tissue homogenates (Ocak et al., 2011), turned out to be
fairly stable in peripheral mouse blood in the present work as well
(Fig. 2). During a previous comparative biodistribution study within
the COST BM0607, 111In-CP04 exhibited high uptake and retention in
A431-CCK2R(+) tumours in mice combined with low kidney retention
(Laverman et al., 2011) and cleared very rapidly from blood and the
background. In the present work identical overall pharmacokinetic pro-
file of 111In-CP04 prepared from the freeze-dried kit (Pawlak et al.,
2016) and by wet-labelling was obtained. This finding is a strong dem-
onstration of the efficacy and suitability of the freeze-dried kit formula-
tion for further use in the clinical trial. The kidney retention of 111In-
CP04 prepared from kit reconstitution was found low in agreement
with previous data. Nevertheless, we aimed to further decrease the kid-
ney retention by co-injecting the plasma expander gelofusine reported
to reduce renal uptake of minigastrin radioligands in rodents
(Gotthardt et al., 2007; Kolenc Peitl et al., 2015). Evidently, this ap-
proach was successful in inducing a significant (P b 0.001) reduction
of the renal uptake of 111In-CP04 in our animalmodel without negative-
ly affecting the radiotracer uptake in the A431-CCK2R(+) xenografts,
and led to significant improvement of the tumour-to-kidney ratios
(Table 3, Fig. 4).Previous experience from small-scale studies performed in MTC pa-
tients using radiolabelled minigastrin analogues at a peptide dose of 5–
10 μg (Froberg et al., 2009) and from the routine pentagastrin test, un-
desirable effects were recorded due to ligand-induced CCK2R-activa-
tion. Adverse reactions included increase of serum calcitonin levels,
increase of heart rate, flushes, mild nausea, paraesthesia in the hands
and dizziness. These effects were mild and disappeared spontaneously
shortly after CCK2R-ligand administration. Biosafety risks related to
the pharmacological effects seem to be acceptable for the intended ap-
plication under certain conditions, such as the administration of the
IMP under strict surveillance of the responsible physician and close
mesh monitoring plan.
Nevertheless, the toxicity of the CP04 precursor was extensively test-
ed in two animal species, revealing the very low toxicity of CP04. The
higher dose of 890 μg/kg tested during the extended acute intravenous
toxicity study in rats (Harlan Study #S47364) caused a marked decrease
in the reticulocyte count, but the reversibility of this effect remains
unknown. Therefore, the lower tested dose 89 μg/kg was set as the
NOAEL. It should be noted that the human equivalent dose (HED)
calculated for this lower NOAEL value was 14.4 μg/kg (HED (μg/kg) =
NOAEL × rat km/human km=89 μg/kg × 6/37= 14.4 μg/kg). By taking
into account a safety factor of 10, the maximum recommended starting
dose (MRSD) for a first-in-human clinical trial would be 1.4 μg/kg.
According to the clinical trial protocol (Eudra-CT No 2015–000,805-
38) only adults with confirmed metastatic MTC will be included in the
study. Subjectswill be intravenously injectedwith either a lower peptide
dose of 10 μg/patient or a higher peptide dose of 50 μg/patient. It should
be noted that both doses are below theMRSD. The rationale for selecting
the above two doses in the clinical protocol are related to restrictions of
CP04 radiolabeling with 200–250 MBq 111In, biosafety considerations
due to peptide-induced side-effects and future theranostic use of 177Lu-
CP04 for PRRT. Specifically, first applications of 111In-CP04 in man will
be performed with the lower peptide dose. Once the biosafety of this
approach is clinically established, the higher peptide dose useful for
translation to 177In-CP04 for PRRT will be applied.
On the other hand, radiation-associated risk assessment is based on
dosimetric calculations derived from animal data. Based on
biodistribution data of 111In-CP04 in healthymice for a 30min-72 h pe-
riod pi dosimetric calculations revealed the highest absorbed doses for
kidneys (Table 5). By employing two different dosimetric scaling op-
tions to translate mouse data to the human situation almost identical
values were obtained. The effective activity dose predicted for 111In-
CP04 in the clinical trial was below 10 mSv (9.9 mSv/220 MBq). Thus,
the effective dose of 111In-CP04 for two hypothetical successive applica-
tions would in fact be lower than that of the licensed product
OctreoScan® for just one similar application in receptor imaging with
SPECT (effective dose of 26 mSv/220 MBq according to SPC). Consider-
ing the severity ofmetastaticMTC this is a justifiable risk for the patient.
The comparison of calculated absorbed dose for kidneys would be
27.5 mGy/220 MBq for 111In-CP04, while the respective value for
Octreoscan® is being estimated at 108.3 mGy/220 MBq.
5. Conclusion
Toxicity studies have indicated the biosafety of CP04 for single intra-
venous injection in human planned in the clinical trial. Radiation-asso-
ciated risk assessment based on dosimetry calculations from animal
data has revealed a justifiable risk for the patients. Furthermore,
biodistribution experiments in tumour-bearingmice have not only con-
firmed indistinguishable in vivo behaviour for 111In-CP04 prepared by
the freeze-dried kit or by wet-labelling, but also the high and CCK2R-
specific tumour-targeting efficacy of 111In-CP04 as well as the role of
gelofusine in significantly reducing renal retention. This data is in favour
of prompt implementation of the freeze-dried kit formulation without
or with gelofusine coinjection in a first multicentre clinical trial in
MTC patients.
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